Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection.
Kaleko M, Bristol JA, Hubert S, Parsley T, Widmer G, Tzipori S, Subramanian P, Hasan N, Koski P, Kokai-Kun J, Sliman J, Jones A, Connelly S. Kaleko M, et al. Among authors: sliman j. Anaerobe. 2016 Oct;41:58-67. doi: 10.1016/j.anaerobe.2016.05.015. Epub 2016 Jun 2. Anaerobe. 2016. PMID: 27262694 Free article.
Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies.
Roberts T, Kokai-Kun JF, Coughlin O, Lopez BV, Whalen H, Bristol JA, Hubert S, Longstreth J, Lasseter K, Sliman J. Roberts T, et al. Among authors: sliman j. Clin Drug Investig. 2016 Sep;36(9):725-734. doi: 10.1007/s40261-016-0420-0. Clin Drug Investig. 2016. PMID: 27283946 Clinical Trial.
The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies.
Kokai-Kun JF, Roberts T, Coughlin O, Sicard E, Rufiange M, Fedorak R, Carter C, Adams MH, Longstreth J, Whalen H, Sliman J. Kokai-Kun JF, et al. Among authors: sliman j. Antimicrob Agents Chemother. 2017 Feb 23;61(3):e02197-16. doi: 10.1128/AAC.02197-16. Print 2017 Mar. Antimicrob Agents Chemother. 2017. PMID: 28052855 Free PMC article. Clinical Trial.
Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial.
Kokai-Kun JF, Roberts T, Coughlin O, Le C, Whalen H, Stevenson R, Wacher VJ, Sliman J. Kokai-Kun JF, et al. Among authors: sliman j. Lancet Infect Dis. 2019 May;19(5):487-496. doi: 10.1016/S1473-3099(18)30731-X. Epub 2019 Mar 15. Lancet Infect Dis. 2019. PMID: 30885591 Clinical Trial.
Erratum: Selection of a cut-off for high- and low-methane producers using a spot-methane breath test: results from a large north American dataset of hydrogen, methane and carbon dioxide measurements in breath.
Gottlieb K, Le C, Wacher V, Sliman J, Cruz C, Porter T, Carter S. Gottlieb K, et al. Among authors: sliman j. Gastroenterol Rep (Oxf). 2018 Aug;6(3):242. doi: 10.1093/gastro/gox015. Epub 2017 Apr 27. Gastroenterol Rep (Oxf). 2018. PMID: 30151210 Free PMC article.
Selection of a cut-off for high- and low-methane producers using a spot-methane breath test: results from a large north American dataset of hydrogen, methane and carbon dioxide measurements in breath.
Gottlieb K, Le C, Wacher V, Sliman J, Cruz C, Porter T, Carter S. Gottlieb K, et al. Among authors: sliman j. Gastroenterol Rep (Oxf). 2017 Aug;5(3):193-199. doi: 10.1093/gastro/gow048. Epub 2017 Jan 27. Gastroenterol Rep (Oxf). 2017. PMID: 28130375 Free PMC article.
15 results